Gocatamig not checked
Merck & Co. · HPN328 · MK-6070
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 2 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- Tested for
- Small Cell Lung Cancer (2 trials), Small-Cell Lung Cancer, Neuroendocrine Carcinoma, Small Cell Lung Cancer Extensive Stage
- Main trialPhase 3
- “Researchers are looking for new ways to treat limited-stage small cell lung cancer (LS-SCLC). LS-SCLC is a type of lung cancer that has not spread from the lung to other parts of the body. Researchers want to learn if gocatamig given with durvalumab can treat LS-SCLC. The main goal of this trial is to learn if participants who receive gocatamig with durvalumab live longer without the cancer getting worse than those who receive durvalumab alone.”In the company’s words, NCT07908537 on ClinicalTrials.gov
- Other names
- HPN328 · MK-6070 · DS-3280
Other drugs for Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up4
- 28 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 15 Feb 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 29 Nov 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 8 Dec 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 8 Dec 2031 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | |
| Phase 1/2Active, not recruiting | 28 Jan 2028 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | |
| Phase 1/2Recruiting | 15 Feb 2029 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | |
| Phase 1/2Recruiting | 29 Nov 2030 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026